Hjem › Tripelnegativ brystkreft › Alabama
Kliniske studier for Tripelnegativ brystkreft i Alabama
11 studier for Tripelnegativ brystkreft søker deltakere på steder i Alabama.
Byer i Alabama
Offisiell studietekst (engelsk)
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- Dothan Hematology & Oncology, Dothan
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07189871PRE-ISPY Phase I/II Oncology Platform Program
- The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT05868226Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Infirmary Cancer Care ( Site 0001), Mobile
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06393374A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- USA Mitchell Cancer Institute ( Site 0090), Mobile
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06841354A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- University of Alabama at Birmingham, Birmingham
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 23. sep. 2026 · NCT06618287Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Alabama Oncology, Birmingham
- Clearview Cancer Institute, Huntsville
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 9. sep. 2026 · NCT05633654Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Birmingham Hematology Associates, Birmingham
RekruttererObservasjonsstudie
Alder 18 til 99 · Alle kjønn · Oppdatert 3. sep. 2026 · NCT07211178Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI)
- UAB, Birmingham
RekruttererTidlig fase 1
Alder 18 til 75 · Kvinner · Oppdatert 17. aug. 2026 · NCT04861077Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- Uni of Alabama at Birmingham, Birmingham
RekruttererFase 1
Alder 18 til 100 · Alle kjønn · Oppdatert 29. jul. 2026 · NCT06562192A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- University of Alabama at Birmingham, Birmingham
- University of Alabama at Birmingham, IDS Pharmacy, Birmingham
- University of Alabama at Birmingham, Birmingham
- og 1 flere
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 22. jul. 2026 · NCT05208762I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- University of Alabama at Birmingham, Birmingham
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 6. mai 2026 · NCT01042379Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.